Oral GLP-1 Drug Orforglipron Achieves Up to 12 kg Weight Loss in Meta-Analysis | Research

The takeaway

Orforglipron, an oral non-peptide GLP-1 RA, produced dose-dependent weight loss up to 12 kg in non-diabetic and 6 kg in diabetic patients with 1.29% HbA1c reduction across 5 RCTs.

12 kg oral weight loss
The oral non-peptide GLP-1 drug orforglipron matched injectable drug weight loss levels at highest doses

What the researchers found

Orforglipron: dose-dependent weight loss up to 12 kg (non-diabetic) and 6 kg (diabetic), HbA1c -1.29%, significant BMI/waist reductions, dose-dependent GI AEs, no pancreatitis signal across 5 RCTs (n=6,140).

Why it matters

An effective oral GLP-1 drug eliminates injection burden, potentially expanding access to millions of patients who avoid injectable therapies.

How the study worked

Meta-analysis of 5 RCTs (n=6,140) from 4 databases through November 2025, evaluating oral orforglipron efficacy and safety in obese adults with and without diabetes.

What this study cannot tell us

Limited long-term data. Dose range still being optimized. GI tolerability at highest doses may limit real-world use. Non-diabetic weight loss data from fewer studies.

How to read the evidence

Meta-analysis of 5 RCTs — strong evidence base. Dose-response relationship well-characterized.

When this study was published

Published in 2025 with data through November 2025.

The bigger picture

Orforglipron represents the first non-peptide oral GLP-1 RA, potentially transforming GLP-1 therapy from injection-based to pill-based treatment.

Questions still open

How does orforglipron compare head-to-head to injectable semaglutide?
Will the pill form improve treatment adherence vs injections?
Is 36 mg the optimal dose or could higher doses be more effective?

Common questions

Is there a GLP-1 pill for weight loss?

Orforglipron is a daily oral GLP-1 drug in late-stage trials showing up to 12 kg weight loss. Unlike other GLP-1 drugs, it is not a peptide and can be taken as a convenient daily pill.

How does it compare to Ozempic injections?

Weight loss with orforglipron approaches injectable GLP-1 drug levels at higher doses (up to 12 kg). The main advantage is pill convenience, though GI side effects are common.

Read the original research

Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.

Diabetes technology & therapeutics, 15209156261420404

View on PubMed ↗Publisher’s paper ↗

Citation

Hammad, Noha; Ramadan, Aya M; Nazmy, Ahmed; Elazab, Ahmed; Abdelaziz, Ahmed. (2026). Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.. Diabetes technology & therapeutics, 15209156261420404. https://doi.org/10.1177/15209156261420404